Alx Oncology Holding Reaches 80-Plus Relative Strength Rating Benchmark
Alx Oncology Holding had its Relative Strength (RS) Rating upgraded from 79 to 82 Tuesday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's proprietary RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
History reveals that the market's biggest winners typically have an RS Rating north of 80 as they launch their biggest climbs.
Alx Oncology Holding has risen more than 5% past a 46.73 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Alx Oncology Holding posted -59% earnings growth in its most recent report. Sales gains came in at -100%.
Alx Oncology Holding earns the No. 181 rank among its peers in the Medical-Biomed/Biotech industry group. Maravai Lifesciences and Biontech Se Ads are also among the group's highest-rated stocks.